Feasibility Study of ARNI Combined with Rosuvastatin Calcium in the Treatment of Patients with Atrial Fibrillation Combined with HFpEF

WEI Wei; XIONG Xiaoqi; LI Bing

doi:10.14033/j.cnki.cfmr.2025.04.005

Abstract：Objective:To investigate the feasibility of angiotensin receptor-neprilysin inhibitor(ARNI)combined with Rosuvastatin Calcium in the treatment of patients with atrial fibrillation(AF)combined with heart failure with preserved ejection fraction(HFpEF).Method:A total of 116 patients with AF combined with HFpEF who admitted to the Department of Cardiology of Liuzhou Liutie Central Hospital from August 2021 to August 2023 were selected as the study objects,they were randomly divided into group A(n=58)and Group B(n=58)using the computer number method of odd and parity numbers.All the patients were treated with anticoagulation and oxygen inhalation,group B was additionally treated with Rosuvastatin Calcium,and group A was additionally treated with ARNI combined with Rosuvastatin Calcium,the efficacy,cardiac function,myocardial injury indexes and adverse reactions of two groups were compared.Result:The total effective rate of group A was higher than that of group B,the difference was statistically significant(P<0.05);after 6 months of treatment,the levels of cardiac function indexes in two groups were improved compared with those before treatment,and the improvement in group A were greater than those in group B,the differences were statistically significant(P<0.05);after 6 months of treatment,myocardial injury indexes in two groups were lower than those before treatment,and those in group A were lower than those in group B,the differences were statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:ARNI combined with Rosuvastatin Calcium is feasible in the treatment of patients with AF combined with HFpEF,which is conducive to the improvement of cardiac function and does not increase the risk of adverse reactions.